Retagen Inc.

Retagen is a biotechnology company specializing in programmable biology and bioengineering. The firm focuses on developing transformational tissue engineering platforms, proteins, and cellular products. By leveraging novel tissue engineering technologies, including systems biology, biomanufacturing, and computational regenerative engineering, Retagen aims to create scalable production capabilities for functional, living tissues. The company’s approach is designed to produce quantifiably enhanced human and animal tissues, providing an innovative infrastructure that integrates scientific research with practical business applications.

Retagen’s work serves to streamline pharmaceutical research and development by providing labs and contract research organizations (CROs) with ready-to-ship tissue models for testing and toxicology assays. By offering these advanced non-animal models, the company seeks to address critical challenges in healthcare, such as the shortage of organ donors and the limitations of current tissue engineering techniques. Through its focus on replacing damaged tissues and advancing cellular technology, Retagen aims to improve both human health outcomes and animal welfare, positioning itself as a provider of advanced bioengineering solutions within the global life sciences industry.